DUBAI, March 29 (Reuters) - A new pharmaceutical plant in Abu Dhabi will start making a COVID-19 vaccine from Chinese pharmaceutical giant Sinopharm later this year under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42 (G42).
The vaccine will be called Hayat-Vax when manufactured in the United Arab Emirates, but is the same BiBP inactivated vaccine that has been administered in the UAE since it was approved by authorities in Decemeber. (Reporting by Lisa Barrington; Editing by Kim Coghill)
Read Again https://www.reuters.com/article/health-coronavirus-emirates-china/new-abu-dhabi-plant-to-manufacture-covid-19-vaccine-from-chinas-sinopharm-idUSS8N2JZ005Bagikan Berita Ini
Related Posts :
Blood Separation System Market Trends, Developments, Opportunities, Manufacture Size and Future Forecasts To 2024 - Ketchum Keystone -- An e-newspaper for the greater Ketchum Idaho community- Gel Wheelchair Cushion Market Trends, Developments, Opportunities, Manufacture Size and Future Forecasts To 2024 - The Connection
- Hikma Inks Five Year Manufacture And Supply Deal With US Non-Profit - Morningstar
- Povidone Iodine (PVP-I) Market by Forecast (2018 – 2025): Key Manufacture – BASF, Ashland, Zen Chemicals, Sunflower, Zhongwei - The Bay State Herald
- Air Bearings Market Trends, Developments, Opportunities, Manufacture Size and Future Forecasts To 2024 - The Connection
0 Response to "New Abu Dhabi plant to manufacture COVID-19 vaccine from China's Sinopharm - Reuters"
Post a Comment